336 related articles for article (PubMed ID: 27832260)
1. Vaginal Testosterone Cream vs Estradiol Vaginal Ring for Vaginal Dryness or Decreased Libido in Women Receiving Aromatase Inhibitors for Early-Stage Breast Cancer: A Randomized Clinical Trial.
Melisko ME; Goldman ME; Hwang J; De Luca A; Fang S; Esserman LJ; Chien AJ; Park JW; Rugo HS
JAMA Oncol; 2017 Mar; 3(3):313-319. PubMed ID: 27832260
[TBL] [Abstract][Full Text] [Related]
2. Intravaginal Testosterone Improves Sexual Satisfaction and Vaginal Symptoms Associated With Aromatase Inhibitors.
Davis SR; Robinson PJ; Jane F; White S; White M; Bell RJ
J Clin Endocrinol Metab; 2018 Nov; 103(11):4146-4154. PubMed ID: 30239842
[TBL] [Abstract][Full Text] [Related]
3. A Randomized, Multicenter, Double-Blind, Study to Evaluate the Safety and Efficacy of Estradiol Vaginal Cream 0.003% in Postmenopausal Women with Vaginal Dryness as the Most Bothersome Symptom.
Archer DF; Kimble TD; Lin FDY; Battucci S; Sniukiene V; Liu JH
J Womens Health (Larchmt); 2018 Mar; 27(3):231-237. PubMed ID: 29193980
[TBL] [Abstract][Full Text] [Related]
4. A Phase II Prospective, Randomized, Double-Blind, Placebo-Controlled and Multicenter Clinical Trial to Assess the Safety of 0.005% Estriol Vaginal Gel in Hormone Receptor-Positive Postmenopausal Women with Early Stage Breast Cancer in Treatment with Aromatase Inhibitor in the Adjuvant Setting.
Sánchez-Rovira P; Hirschberg AL; Gil-Gil M; Bermejo-De Las Heras B; Nieto-Magro C
Oncologist; 2020 Dec; 25(12):e1846-1854. PubMed ID: 32459035
[TBL] [Abstract][Full Text] [Related]
5. Topical testosterone for breast cancer patients with vaginal atrophy related to aromatase inhibitors: a phase I/II study.
Witherby S; Johnson J; Demers L; Mount S; Littenberg B; Maclean CD; Wood M; Muss H
Oncologist; 2011; 16(4):424-31. PubMed ID: 21385795
[TBL] [Abstract][Full Text] [Related]
6. Local oestrogen for vaginal atrophy in postmenopausal women.
Lethaby A; Ayeleke RO; Roberts H
Cochrane Database Syst Rev; 2016 Aug; 2016(8):CD001500. PubMed ID: 27577677
[TBL] [Abstract][Full Text] [Related]
7. A comparative study of safety and efficacy of continuous low dose oestradiol released from a vaginal ring compared with conjugated equine oestrogen vaginal cream in the treatment of postmenopausal urogenital atrophy.
Ayton RA; Darling GM; Murkies AL; Farrell EA; Weisberg E; Selinus I; Fraser ID
Br J Obstet Gynaecol; 1996 Apr; 103(4):351-8. PubMed ID: 8605133
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of Vaginal Estradiol or Vaginal Moisturizer vs Placebo for Treating Postmenopausal Vulvovaginal Symptoms: A Randomized Clinical Trial.
Mitchell CM; Reed SD; Diem S; Larson JC; Newton KM; Ensrud KE; LaCroix AZ; Caan B; Guthrie KA
JAMA Intern Med; 2018 May; 178(5):681-690. PubMed ID: 29554173
[TBL] [Abstract][Full Text] [Related]
9. Ultra-low-dose estriol and Lactobacillus acidophilus vaginal tablets (Gynoflor(®)) for vaginal atrophy in postmenopausal breast cancer patients on aromatase inhibitors: pharmacokinetic, safety, and efficacy phase I clinical study.
Donders G; Neven P; Moegele M; Lintermans A; Bellen G; Prasauskas V; Grob P; Ortmann O; Buchholz S
Breast Cancer Res Treat; 2014 Jun; 145(2):371-9. PubMed ID: 24718774
[TBL] [Abstract][Full Text] [Related]
10. The effect of transdermal and vaginal estrogen therapy on markers of postmenopausal estrogen status.
Gupta P; Ozel B; Stanczyk FZ; Felix JC; Mishell DR
Menopause; 2008; 15(1):94-7. PubMed ID: 17882008
[TBL] [Abstract][Full Text] [Related]
11. Changes in serum estradiol levels with Estring in postmenopausal women with breast cancer treated with aromatase inhibitors.
Streff A; Chu-Pilli M; Stopeck A; Chalasani P
Support Care Cancer; 2021 Jan; 29(1):187-191. PubMed ID: 32328775
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of ultra-low dose 0.005% estriol vaginal gel for the treatment of vulvovaginal atrophy in postmenopausal women with early breast cancer treated with nonsteroidal aromatase inhibitors: a phase II, randomized, double-blind, placebo-controlled trial.
Hirschberg AL; Sánchez-Rovira P; Presa-Lorite J; Campos-Delgado M; Gil-Gil M; Lidbrink E; Suárez-Almarza J; Nieto-Magro C
Menopause; 2020 May; 27(5):526-534. PubMed ID: 32049923
[TBL] [Abstract][Full Text] [Related]
13. A randomized, double-blind, placebo-controlled phase 2 pilot trial evaluating a novel, vaginal softgel capsule containing solubilized estradiol.
Pickar JH; Amadio JM; Hill JM; Bernick BA; Mirkin S
Menopause; 2016 May; 23(5):506-10. PubMed ID: 26836245
[TBL] [Abstract][Full Text] [Related]
14. A randomized, multicenter, double-blind study to evaluate the safety and efficacy of estradiol vaginal cream 0.003% in postmenopausal women with dyspareunia as the most bothersome symptom.
Kroll R; Archer DF; Lin Y; Sniukiene V; Liu JH
Menopause; 2018 Feb; 25(2):133-138. PubMed ID: 28926514
[TBL] [Abstract][Full Text] [Related]
15. Local oestrogen for vaginal atrophy in postmenopausal women.
Suckling J; Lethaby A; Kennedy R
Cochrane Database Syst Rev; 2003; (4):CD001500. PubMed ID: 14583935
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of vaginally applied estrogen, testosterone, or polyacrylic acid on sexual function in postmenopausal women: a randomized controlled trial.
Fernandes T; Costa-Paiva LH; Pinto-Neto AM
J Sex Med; 2014 May; 11(5):1262-70. PubMed ID: 24612478
[TBL] [Abstract][Full Text] [Related]
17. Vaginal estrogen products in hormone receptor-positive breast cancer patients on aromatase inhibitor therapy.
Sulaica E; Han T; Wang W; Bhat R; Trivedi MV; Niravath P
Breast Cancer Res Treat; 2016 Jun; 157(2):203-210. PubMed ID: 27178335
[TBL] [Abstract][Full Text] [Related]
18. Vaginal estrogen therapy in postmenopausal breast cancer patients treated with aromatase inhibitors.
Moegele M; Buchholz S; Seitz S; Ortmann O
Arch Gynecol Obstet; 2012 May; 285(5):1397-402. PubMed ID: 22212649
[TBL] [Abstract][Full Text] [Related]
19. Hormonal, metabolic, and endometrial safety of testosterone vaginal cream versus estrogens for the treatment of vulvovaginal atrophy in postmenopausal women: a randomized, placebo-controlled study.
Fernandes T; Pedro AO; Baccaro LF; Costa-Paiva LH
Menopause; 2018 Jun; 25(6):641-647. PubMed ID: 29462095
[TBL] [Abstract][Full Text] [Related]
20. Local oestrogen for vaginal atrophy in postmenopausal women.
Suckling J; Lethaby A; Kennedy R
Cochrane Database Syst Rev; 2006 Oct; (4):CD001500. PubMed ID: 17054136
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
